TY - JOUR
T1 - Therapeutic polymeric nanoparticles and the methods of making and using thereof
T2 - A patent evaluation of WO2015036792
AU - Sarvagalla, Sailu
AU - Hsieh, Hsing Pang
AU - Coumar, Mohane Selvaraj
N1 - Funding Information:
This work was supported by grants (SR/FT/LS-64/2011) of Science & Engineering Research Board, Govt. of India for MS Coumar. S Sarvagalla gratefully acknowledges the Department of Biotechnology, Govt. of India, for a Junior Research Fellowship (DBT-JRF/2012-13/80). HP Hsieh acknowledges financial support from National Health Research Institutes, Taiwan. The authors, MS Coumar and S Sarvagalla are employees of Pondicherry University, India, and HP Hsieh is employee of National Health Research Institutes, Taiwan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/7/2
Y1 - 2016/7/2
N2 - Evaluation of the patent application WO2015036792 claiming therapeutic polymeric nanoparticles loaded with AZD1152-hqpa (aurora kinase inhibitor), and methods of making and using same for the treatment of cancer, is described. The claimed polymeric nano-formulations containing hydrophobic acid significantly improved the pharmacokinetic profiles (slow/sustained drug release profile) of the drug AZD1152-hqpa, as compared to the control agent (AZD1152). Drug efficacy and tolerability were also improved, and toxicity decreased in in vivo animal experiments, resulting in a better therapeutic index for the nano-formulation. Hence, the nano-formulated AZD1152-hqpa could be tested in the clinic at a dose level similar to, or higher than, that used for AZD1152, with lower incidence of toxicity.
AB - Evaluation of the patent application WO2015036792 claiming therapeutic polymeric nanoparticles loaded with AZD1152-hqpa (aurora kinase inhibitor), and methods of making and using same for the treatment of cancer, is described. The claimed polymeric nano-formulations containing hydrophobic acid significantly improved the pharmacokinetic profiles (slow/sustained drug release profile) of the drug AZD1152-hqpa, as compared to the control agent (AZD1152). Drug efficacy and tolerability were also improved, and toxicity decreased in in vivo animal experiments, resulting in a better therapeutic index for the nano-formulation. Hence, the nano-formulated AZD1152-hqpa could be tested in the clinic at a dose level similar to, or higher than, that used for AZD1152, with lower incidence of toxicity.
UR - http://www.scopus.com/inward/record.url?scp=84969903037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969903037&partnerID=8YFLogxK
U2 - 10.1080/13543776.2016.1188919
DO - 10.1080/13543776.2016.1188919
M3 - Article
C2 - 27167102
AN - SCOPUS:84969903037
SN - 1354-3776
VL - 26
SP - 751
EP - 755
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
IS - 7
ER -
